Protocol detail

Isolation and Characterization of Antibodies

Find Similar Protocols

Rituximab (Genentech, San Francisco, CA) was acquired through a drug exchange program at Duke University Medical Center, Department of Hematology and Oncology. Human CFH mAb 7968 was generated by cloning and expressing antibody genes derived from a single B cell as previously described [12 (link)]. The IgG1subclass-matched negative control antibody 7B2 recognizes gp41, an HIV-1 envelope glycoprotein, and was a gift of Dr. H. Liao of the Duke Human Vaccine Institute. The rat anti-human CD59 mAb YTH53.1 was obtained from Santa Cruz Biotechnology (Dallas, TX). The FITC mouse anti-human CD20 mAb 2H7 was obtained from BD Biosciences (San Jose, CA).

Free full text: Click here

Winkler M.T., Bushey R.T., Gottlin E.B., Campa M.J., Guadalupe E.S., Volkheimer A.D., Weinberg J.B, & Patz EF J.r. (2017). Enhanced CDC of B cell chronic lymphocytic leukemia cells mediated by rituximab combined with a novel anti-complement factor H antibody. PLoS ONE, 12(6), e0179841.

Publication 2017

Rituximab YTH53.1

Antibody Antibody genes B cell Cd59 Drug Fitc Glycoprotein Hiv 1 Human Mouse Oncology Rituximab Vaccine

Top 5 similar protocols

Variable analysis

independent variables

Rituximab (Genentech, San Francisco, CA) acquired through a drug exchange program at Duke University Medical Center, Department of Hematology and Oncology
Human CFH mAb 7968 generated by cloning and expressing antibody genes derived from a single B cell as previously described [12]
IgG1subclass-matched negative control antibody 7B2 recognizing gp41, an HIV-1 envelope glycoprotein, provided by Dr. H. Liao of the Duke Human Vaccine Institute
Rat anti-human CD59 mAb YTH53.1 obtained from Santa Cruz Biotechnology (Dallas, TX)
FITC mouse anti-human CD20 mAb 2H7 obtained from BD Biosciences (San Jose, CA)

dependent variables

Not explicitly mentioned

control variables

Not explicitly mentioned

positive controls

Rituximab (Genentech, San Francisco, CA) acquired through a drug exchange program at Duke University Medical Center, Department of Hematology and Oncology

negative controls

IgG1subclass-matched negative control antibody 7B2 recognizing gp41, an HIV-1 envelope glycoprotein, provided by Dr. H. Liao of the Duke Human Vaccine Institute

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!